Abstract
CD133 positive (CD133+) cells are cancer stem cells in glioblastoma that are associated with poor prognosis and resistance to radiotherapy. However, the role of CD133 in chemoresistance is inconclusive, although recent studies suggest that increased CD133 expression may lead to increased cisplatin resistance under certain circumstances. In this study, we further explored the mechanism underlying CD133-mediated cisplatin resistance in glioblastoma stem cells. We sorted human glioblastoma T98G and U87MG cells into CD133+ and CD133− pools and measured apoptosis and CD133 expression levels in response to cisplatin treatment. We predicted candidate microRNAs that might target CD133 and assessed their levels in cisplatin-treated CD133+ cells. Finally, we overexpressed miR-29a in CD133+ cells and tested its effects in cisplatin-mediated apoptosis and survival of CD133+ tumor bearing mice receiving cisplatin treatment. We found that CD133+ glioblastoma stem cells showed more resistance to cisplatin treatment. Cisplatin increased CD133 expression by suppressing miR-29a levels. MiR-29a overexpression improved sensitivity of cisplatin in CD133+ cells and significantly suppressed tumor growth in CD133+ tumor bearing mice in response to cisplatin treatment. Our data show that miR-29a ameliorates CD133-mediated chemoresistance in glioblastoma stem cells, suggesting it as a potential therapeutic target for treating glioblastoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Agrawal R, Pandey P, Jha P, Dwivedi V, Sarkar C, Kulshreshtha R (2014) Hypoxic signature of microRNAs in glioblastoma: insights from small RNA deep sequencing. BMC Genomics 15:686. https://doi.org/10.1186/1471-2164-15-686
Ahmed EM, Bandopadhyay G, Coyle B, Grabowska A (2018) A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells. Cell Oncol (Dordr) 41:319–328. https://doi.org/10.1007/s13402-018-0374-8
Alifieris C, Trafalis DT (2015) Glioblastoma multiforme: pathogenesis and treatment. Pharmacol Ther 152:63–82. https://doi.org/10.1016/j.pharmthera.2015.05.005
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760. https://doi.org/10.1038/nature05236
Brescia P, Ortensi B, Fornasari L, Levi D, Broggi G, Pelicci G (2013) CD133 is essential for glioblastoma stem cell maintenance. Stem Cells 31:857–869. https://doi.org/10.1002/stem.1317
Coluccia D, Figueiredo CA, Wu MYJ, Riemenschneider AN, Diaz R, Luck A, Smith C, Das S, Ackerley C, O’Reilly M, Hynynen K, Rutka JT (2018) Enhancing glioblastoma treatment using cisplatin-gold-nanoparticle conjugates and targeted delivery with magnetic resonance-guided focused ultrasound. Nanomedicine 14:1137–1148. https://doi.org/10.1016/j.nano.2018.01.021
Han M, Guo L, Zhang Y, Huang B, Chen A, Chen W, Liu X, Sun S, Wang K, Liu A, Li X (2016) Clinicopathological and prognostic significance of CD133 in glioma patients: a meta-analysis. Mol Neurobiol 53:720–727. https://doi.org/10.1007/s12035-014-9018-9
Jacobs SS, Fox E, Dennie C, Morgan LB, McCully CL, Balis FM (2005) Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates. Clin Cancer Res 11:1669–1674. https://doi.org/10.1158/1078-0432.CCR-04-1807
Jue TR, McDonald KL (2016) The challenges associated with molecular targeted therapies for glioblastoma. J Neuro-Oncol 127:427–434. https://doi.org/10.1007/s11060-016-2080-6
Kozovska Z, Gabrisova V, Kucerova L (2014) Colon cancer: cancer stem cells markers, drug resistance and treatment. Biomed Pharmacother 68:911–916. https://doi.org/10.1016/j.biopha.2014.10.019
Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CL, Rich JN (2015) Cancer stem cells in glioblastoma. Genes Dev 29:1203–1217. https://doi.org/10.1101/gad.261982.115
Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5:67. https://doi.org/10.1186/1476-4598-5-67
Liu YP, Yang CJ, Huang MS, Yeh CT, Wu ATH, Lee YC, Lai TC, Lee CH, Hsiao YW, Lu J, Shen CN, Lu PJ, Hsiao M (2013) Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling. Cancer Res 73:406–416. https://doi.org/10.1158/0008-5472.CAN-12-1733
Nadal R, Ortega FG, Salido M, Lorente JA, Rodríguez-Rivera M, Delgado-Rodríguez M, Macià M, Fernández A, Corominas JM, García-Puche JL, Sánchez-Rovira P, Solé F, Serrano MJ (2013) CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy. Int J Cancer 133:2398–2407. https://doi.org/10.1002/ijc.28263
Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R, Bayani J, Head R, Lee M, Bernstein M, Squire JA, Smith A, Dirks P (2009) Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4:568–580. https://doi.org/10.1016/j.stem.2009.03.014
Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105–111. https://doi.org/10.1038/35102167
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432:396–401. https://doi.org/10.1038/nature03128
Stopschinski BE, Beier CP, Beier D (2013) Glioblastoma cancer stem cells—from concept to clinical application. Cancer Lett 338:32–40. https://doi.org/10.1016/j.canlet.2012.05.033
Tamura K, Aoyagi M, Wakimoto H, Ando N, Nariai T, Yamamoto M, Ohno K (2010) Accumulation of CD133-positive glioma cells after high-dose irradiation by gamma knife surgery plus external beam radiation. J Neurosurg 113:310–318. https://doi.org/10.3171/2010.2.JNS091607
Tan M, Wu J, Cai Y (2013) Suppression of Wnt signaling by the miR-29 family is mediated by demethylation of WIF-1 in non-small-cell lung cancer. Biochem Biophys Res Commun 438:673–679. https://doi.org/10.1016/j.bbrc.2013.07.123
Trehoux S et al (2015) Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells. Biochim Biophys Acta 1853:2392–2403. https://doi.org/10.1016/j.bbamcr.2015.05.033
van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, de Vries HE (2015) Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat 19:1–12. https://doi.org/10.1016/j.drup.2015.02.002
Yang L, Yan Z, Wang Y, Ma W, Li C (2016) Down-expression of miR-154 suppresses tumourigenesis in CD133(+) glioblastoma stem cells. Cell Biochem Funct 34:404–413. https://doi.org/10.1002/cbf.3201
Yu VY, Nguyen D, Pajonk F, Kupelian P, Kaprealian T, Selch M, Low DA, Sheng K (2015) Incorporating cancer stem cells in radiation therapy treatment response modeling and the implication in glioblastoma multiforme treatment resistance. Int J Radiat Oncol Biol Phys 91:866–875. https://doi.org/10.1016/j.ijrobp.2014.12.004
Zollner H, Hahn SA, Maghnouj A (2014) Lentiviral overexpression of miRNAs. Methods Mol Biol 1095:177–190. https://doi.org/10.1007/978-1-62703-703-7_15
Funding
This work was supported by the National Natural Science Foundation of China (81401032) and the National Natural Science Foundation of Hebei Province (H2015206309).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical Approval
All applicable international, national, and institutional guidelines for the care and use of animals were followed.
Conflict of Interest
The authors have no conflict of interest to disclose.
Rights and permissions
About this article
Cite this article
Yang, L., Li, N., Yan, Z. et al. MiR-29a-Mediated CD133 Expression Contributes to Cisplatin Resistance in CD133+ Glioblastoma Stem Cells. J Mol Neurosci 66, 369–377 (2018). https://doi.org/10.1007/s12031-018-1177-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-018-1177-0